Every month a promising new drug languishes in regulatory limbo costs pharmaceutical companies real money. Not thousands. Millions. And while researchers and executives fret over clinical outcomes and market positioning, an unglamorous culprit often sits at the heart of the delay: paperwork.
Enter Ritivel, a San Francisco startup emerging from Y Combinator with a familiar pitch wrapped in an unfamiliar security model. The company says its AI platform can collapse regulatory document drafting from weeks into minutes—Clinical Study Reports, Investigational New Drug applications, the sprawling CTD modules that run thousands of pages. The twist? Everything runs on-premises. Customer data never sees the cloud, never trains a model, never leaves the building.
Whether that's enough to crack open a market dominated by incumbents and haunted by trust issues is the question the three-person team now faces.
Speed Meets Paranoia
Ritivel's founding trio came from different corners of enterprise tech. CEO Pavan Kalyan Tankala and CTO Nirmit Arora both worked at Microsoft Research; COO Gunin Gupta arrived from consulting firm Kearney. Together, they've designed a platform around a specific set of regulatory nightmares: the documents that gate every major drug approval.
Their launch materials make bold claims. CTD Module 5 literature reviews that typically consume days? Minutes, they say, with automated PubMed searches and cross-referenced summaries. Clinical Study Reports? Feed in the protocol and statistical analysis plan, get non-data sections instantly. After data lock, the system promises biostatistical analyses, auto-generated tables and figures, then conversion into narrative sections—all at what the company calls "12× faster" than traditional methods.
Hard to verify, of course. Ritivel hasn't named pilot customers or published independent benchmarks. For a company that launched relatively recently, that's not unusual. But in an industry where a single error in a regulatory submission can trigger months of delays or outright rejections, extraordinary claims need extraordinary evidence.
And they know it.
The Hallucination Problem
In a blog post from earlier this year, Gupta laid out what keeps him up at night: AI hallucinations in documents that determine whether drugs reach patients. He referenced FDA guidance on using AI to support regulatory decisions and sketched a seven-step credibility assessment framework. That anxiety about accuracy shaped the entire product.
Ritivel promises "100% reproducibility"—deterministic outputs that won't shift between runs. Every claim in a generated document traces to a specific source, word by word. The platform deploys on customer infrastructure, with what the company describes as zero data retention, no model training on proprietary information, air-gapped capability if needed, and 256-bit encryption with role-based access.
It's a security posture bordering on the obsessive, which may be precisely the point. Life sciences companies live in terror of data breaches and regulatory missteps. Ritivel is betting that paranoia sells.
A Crowded Space Gets Tighter
The regulatory AI market didn't wait for Ritivel to wake up. Weave Bio announced $10 million in seed funding back in mid-2024 for AutoIND, its platform focused on IND submissions, with backing from Innovation Endeavors and Magnetic Ventures. By late 2025, Weave published research suggesting human-AI collaboration could boost efficiency in regulatory writing—though "boost efficiency" covers a lot of ground.
Established players are circling too. Veeva Systems has discussed agentic AI for regulatory workflows at industry conferences. Clarivate launched a regulatory assistant within its Cortellis platform. SyneticX promotes real-time mapping of submissions against ICH CTD guidelines. Even the FDA updated its "Artificial Intelligence for Drug Development" guidance jointly with European regulators, signaling that oversight is evolving alongside the technology.
Industry surveys hint at why startups see opportunity. A Veeva MedTech benchmark from mid-2025 found only 17 percent of respondents rated their regulatory data quality as excellent. Half lacked full confidence in their data. That's a wedge—if you can prove your system delivers better consistency and traceability.
Ritivel outputs documents directly to Microsoft Word, formatted for FDA submission standards, with citations linking to source material. The platform connects to SharePoint and Veeva for document retrieval, integrates with Outlook for automated regulatory correspondence follow-ups. There's also a free regulatory search tool—no signup required—querying FDA, ICH, and product-specific guidances. Strategic customer acquisition, maybe. Or just table stakes.
Trust Is the Product
CB Insights data suggests Ritivel raised around $500,000 via convertible note, likely the standard Y Combinator deal. The company incorporated a subsidiary in India in late 2025 and currently lists no open positions. Three team members. No public case studies. No named customers. No published validation of that "12× faster" claim beyond internal assertions.
None of that is unusual for a startup fresh out of an accelerator cohort, but it does mean the real test lies ahead.
And here's the uncomfortable truth: pharmaceutical and biotech companies don't hand over their most sensitive regulatory documents lightly, on-premises deployment or not. These are submissions worth hundreds of millions—sometimes billions—in potential revenue. A single misstep in a regulatory filing can derail years of research and development. Trust in this context isn't a nice-to-have; it's the entire product.
Ritivel's founders are banking on precision, traceability, and a near-obsessive approach to data security. One document at a time, they're hoping to prove that AI can handle the unglamorous, high-stakes work that keeps drugs bottled up in bureaucracy.
Whether the industry buys in remains an open question. The technology may be ready. The skepticism, however—especially around a three-person team promising to automate processes that have historically required armies of regulatory specialists—will take longer to overcome.
